Gilead's Bictegravir Demonstrates Broad Non-Inferiority, But Will That Suffice?

30 May 2017

Having lost market share in recent years to HIV regimens containing ViiV's Tivicay, will a showing of non-inferiority across four head-to-head Phase III studies give bictegravir the market edge Gilead seeks?

Gilead Sciences Inc. revealed success demonstrating non-inferiority in four Phase III trials testing its investigational integrase inhibitor bictegravir head-to-head against other HIV therapy regimens, but it remains unclear whether these findings will give the virology specialist an edge against ViiV Healthcare's Tivicay (dolutegravir).

The Foster City, Calif.-based firm reported May 30 that bictegravir met the standard for non-inferiority in studies using comparator regimens...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Quick Listen: Scrip’s Five Must-Know Things

16 Jun 2025

• By Ian Haydock

In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.

In Brief: Gilead HIV Trials On Hold Over Safety Signal

11 Jun 2025

• By Sushmita Panda

The FDA has paused Gilead’s HIV trials of GS-1720 and GS-4182 over safety concerns. The company’s upcoming PrEP PDUFA looks to be unaffected.

In Brief: PolyPid’s D-PLEX100 Aces Phase III Trial, US Partner, Submission Eyed

11 Jun 2025

• By Sushmita Panda

PolyPid's D-PLEX100 meets Phase III endpoints this time around, significantly reducing surgical point infections in abdominal colorectal surgery, and is set for a US approval submission early next year.

With ACIP Upheaval, Merck & Co. Among Those Left In A Lurch

10 Jun 2025

• By Jessica Merrill and Bridget Silverman

Merck’s newly approved Enflonsia for RSV is one of the products that was expected to be recommended for use by the CDC advisory committee in June.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

12 Jun 2025

• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.